Women lose ovarian function approximately twenty-five years before they die. Menopause is one of the largest known phase transitions in human aging biology, and the four-year life-expectancy difference between sexes is partly explained by this reproductive-aging differential. Andropause is the corresponding male axis. The CureForge Reproductive Longevity & Hormonal Aging Institute is the federation’s research engine for that biology. Eleven specialized AI systems collaborate across ovarian aging biomarkers, menopause-delay therapeutic design, andropause biology, in-vitro fertilization and in-vitro maturation extension, endometrial aging, postmenopausal cardiovascular and cognitive aging where women have approximately twice the Alzheimer’s risk of men, fertility preservation, hormone replacement optimization, and oocyte and sperm cryobiology coordinated with the federation’s cryonics institute. Every clinical recommendation is reviewed by qualified reproductive endocrinologists.
Value proposition: - Menopause delay as the largest reversible aging phase transition
- Coordinated post-menopausal cardiovascular and cognitive risk reduction
- Cross-coordination with cryonics for oocyte and sperm preservation